This company has been acquired
AVEO Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Key information
-2.90%
Earnings growth rate
32.67%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 51.00% |
| Return on equity | -100.67% |
| Net Margin | -30.79% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
AVEO Oncology shares jumped on acqusition by LG Chem for $15.00 per share in cash
Oct 18Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money
Oct 04
A Current Assessment On AVEO Pharmaceuticals
Aug 15Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt
Jun 21AVEO Pharmaceuticals Is Primed For A Breakout
May 24Here's What Analysts Are Forecasting For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) After Its Annual Results
Mar 17AVEO Pharmaceuticals: Finally Ready To Reboot
Mar 09AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 03AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 23AVEO Pharmaceuticals: Sticking To The Plan
Oct 29AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment
Jul 24Revenue & Expenses Breakdown
How AVEO Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 94 | -29 | 68 | 13 |
| 30 Jun 22 | 79 | -36 | 65 | 10 |
| 31 Mar 22 | 61 | -41 | 63 | 5 |
| 31 Dec 21 | 42 | -53 | 61 | 0 |
| 30 Sep 21 | 26 | -58 | 54 | 20 |
| 30 Jun 21 | 14 | -56 | 45 | 13 |
| 31 Mar 21 | 7 | -49 | 34 | 5 |
| 31 Dec 20 | 6 | -36 | 22 | 0 |
| 30 Sep 20 | 6 | -29 | 16 | 0 |
| 30 Jun 20 | 28 | -4 | 13 | 0 |
| 31 Mar 20 | 28 | 0 | 12 | 0 |
| 31 Dec 19 | 29 | 9 | 11 | 0 |
| 30 Sep 19 | 30 | 36 | 11 | 0 |
| 30 Jun 19 | 6 | -3 | 11 | 0 |
| 31 Mar 19 | 6 | 4 | 11 | 0 |
| 31 Dec 18 | 5 | -5 | 11 | 0 |
| 30 Sep 18 | 4 | -24 | 11 | 0 |
| 30 Jun 18 | 6 | -28 | 10 | 0 |
| 31 Mar 18 | 6 | -65 | 9 | 0 |
| 31 Dec 17 | 8 | -65 | 9 | 0 |
| 30 Sep 17 | 8 | -74 | 9 | 0 |
| 30 Jun 17 | 4 | -53 | 9 | 0 |
| 31 Mar 17 | 4 | -28 | 8 | 0 |
| 31 Dec 16 | 3 | -27 | 8 | 0 |
| 30 Sep 16 | 6 | -28 | 10 | 0 |
| 30 Jun 16 | 20 | -15 | 10 | 0 |
| 31 Mar 16 | 20 | -12 | 11 | 0 |
Quality Earnings: AVEO is currently unprofitable.
Growing Profit Margin: AVEO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AVEO is unprofitable, and losses have increased over the past 5 years at a rate of 2.9% per year.
Accelerating Growth: Unable to compare AVEO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVEO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).
Return on Equity
High ROE: AVEO has a negative Return on Equity (-100.67%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/21 15:19 |
| End of Day Share Price | 2023/01/19 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AVEO Pharmaceuticals, Inc. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| James Birchenough | BMO Capital Markets Equity Research |
| Madhu Kumar | B. Riley Securities, Inc. |